Biotechnology

Pfizer buys Array BioPharma for $11.4 billion

A scientist works in a cancer research lab.
An Array BioPharma research lab. Photo: Paul Aiken/Digital First Media/Boulder Daily Camera via Getty Images

Pfizer has agreed to buy Array BioPharma for $48 per share, or $11.4 billion after including Array's debt. Array had never traded above $30 per share before this acquisition.

The bottom line: This is another deep-pocketed move into cancer medicines from a Big Pharma company. Array already is selling 2 FDA-approved drugs for melanoma, and Pfizer is banking on Array's other in-progress therapies to treat patients with colon cancer.

Dassault Systemes buying Medidata in $5.8 billion deal

Dassault Systemes CEO Bernard Charles speaks behind a podium.
Dassault Systemes CEO Bernard Charles. Photo: Vincent Isore/IP3/Getty Images

Dassault Systemes, a French maker of industrial software and technology, is buying New York-based health data provider Medidata in a deal worth $5.8 billion.

The bottom line: Medidata registered a $52 million profit last year on $636 million of revenue, but Dassault is betting that more pharmaceutical and medical device companies will use Medidata's software to help their products clear clinical trials. More than 1,000 health care companies already use Medidata for clinical trial work.